P50 CA90270/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2001	1
2002	3
2003	3
2004	5
2005	7
2006	6
2007	2
2008	6
2009	5
2010	1
2011	1
2024	0

1

Imaging of angiogenesis: from microscope to clinic.

McDonald DM, Choyke PL. McDonald DM, et al. Nat Med. 2003 Jun;9(6):713-25. doi: 10.1038/nm0603-713. Nat Med. 2003. PMID: 12778170 Review.

2

Cellular abnormalities of blood vessels as targets in cancer.

Baluk P, Hashizume H, McDonald DM. Baluk P, et al. Curr Opin Genet Dev. 2005 Feb;15(1):102-11. doi: 10.1016/j.gde.2004.12.005. Curr Opin Genet Dev. 2005. PMID: 15661540 Review.

3

The central role of osteoblasts in the metastasis of prostate cancer.

Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. Choueiri MB, et al. Cancer Metastasis Rev. 2006 Dec;25(4):601-9. doi: 10.1007/s10555-006-9034-y. Cancer Metastasis Rev. 2006. PMID: 17160554 Review.

4

Biology and clinical management of prostate cancer bone metastasis.

Ye XC, Choueiri M, Tu SM, Lin SH. Ye XC, et al. Front Biosci. 2007 May 1;12:3273-86. doi: 10.2741/2311. Front Biosci. 2007. PMID: 17485298 Review.

5

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Tsavachidou D, et al. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20. doi: 10.1093/jnci/djn512. Epub 2009 Feb 24. J Natl Cancer Inst. 2009. PMID: 19244175 Free PMC article. Clinical Trial.

6

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.

Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Loberg RD, et al. J Clin Oncol. 2005 Nov 10;23(32):8232-41. doi: 10.1200/JCO.2005.03.0841. J Clin Oncol. 2005. PMID: 16278478 Review.

7

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.

Logothetis CJ, Navone NM, Lin SH. Logothetis CJ, et al. Clin Cancer Res. 2008 Mar 15;14(6):1599-602. doi: 10.1158/1078-0432.CCR-07-4603. Clin Cancer Res. 2008. PMID: 18347159 Review.

8

Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification.

Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P. Efstathiou E, et al. Eur Urol. 2010 Jun;57(6):1030-8. doi: 10.1016/j.eururo.2009.10.020. Epub 2009 Oct 17. Eur Urol. 2010. PMID: 19853370 Free PMC article.

9

Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma.

Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM. Ozawa MG, et al. Cancer. 2005 Nov 15;104(10):2104-15. doi: 10.1002/cncr.21436. Cancer. 2005. PMID: 16208706 Free article.

10

NudC is required for Plk1 targeting to the kinetochore and chromosome congression.

Nishino M, Kurasawa Y, Evans R, Lin SH, Brinkley BR, Yu-Lee LY. Nishino M, et al. Curr Biol. 2006 Jul 25;16(14):1414-21. doi: 10.1016/j.cub.2006.05.052. Curr Biol. 2006. PMID: 16860740 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

39 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year